Mach Maciej, Giba Aleksandra, Miedziaszczyk Milosz, Bryla Adrian, Szkutnik-Fiedler Danuta
Department of General, Vascular, Endocrine, and Transplant Surgery, Medical University of Warsaw, Warsaw, POL.
Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Poznań, POL.
Cureus. 2025 Aug 22;17(8):e90755. doi: 10.7759/cureus.90755. eCollection 2025 Aug.
The NaV1.8 sodium channel plays a key role in the transmission of pain signals in peripheral sensory neurons. Suzetrigine is a selective NaV1.8 inhibitor developed as a non-opioid analgesic. Its action is limited to sensory neurons, reducing the risk of adverse effects associated with non-selective sodium channel blockers. Phase II and III clinical trials have demonstrated the high efficacy of suzetrigine in managing postoperative pain, along with good tolerability. Adverse events, such as dizziness or drowsiness, were rare and generally mild to moderate in intensity. The drug did not cause respiratory depression or addiction, which distinguishes it from opioids. Ongoing pharmacokinetic studies and long-term observations aim to further define the drug's safety profile and its potential use in patients with comorbid conditions. Suzetrigine may offer an effective and safe alternative to opioids in pain treatment.
Nav1.8钠通道在周围感觉神经元的疼痛信号传递中起关键作用。舒泽曲明是一种作为非阿片类镇痛药开发的选择性Nav1.8抑制剂。其作用仅限于感觉神经元，降低了与非选择性钠通道阻滞剂相关的不良反应风险。II期和III期临床试验已证明舒泽曲明在管理术后疼痛方面具有高效性，且耐受性良好。头晕或嗜睡等不良事件罕见，强度一般为轻至中度。该药物不会引起呼吸抑制或成瘾，这使其有别于阿片类药物。正在进行的药代动力学研究和长期观察旨在进一步明确该药物的安全性概况及其在合并症患者中的潜在用途。在疼痛治疗中，舒泽曲明可能为阿片类药物提供一种有效且安全的替代方案。
